The BCKDK Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1. This polyclonal pool features targeted disruption of BCKDK, the gene encoding branched-chain ketoacid dehydrogenase kinase, providing a loss-of-function model for studying branched-chain amino acid (BCAA) metabolism and its crosstalk with oncogenic signaling. As a polyclonal population, these cells maintain the genetic heterogeneity inherent to CRISPR/Cas9-mediated gene disruption, facilitating robust functional analyses without clonal selection.
The parental SK-HEP-1 line was established from ascitic fluid of a liver adenocarcinoma patient and is widely used as a model for hepatocellular carcinoma. SK-HEP-1 cells display endothelial-like properties, making them particularly suitable for studies of tumor angiogenesis, metastasis, and metabolic adaptation in liver cancer. Their amenability to genetic manipulation and biochemical assays provides a versatile platform for dissecting hepatic malignancy mechanisms.
BCKDK negatively regulates BCAA catabolism by phosphorylating BCKDHA (E1?? subunit of the branched-chain ??-ketoacid dehydrogenase complex, BCKDC), thereby inactivating this rate-limiting enzyme in valine, leucine, and isoleucine degradation. BCKDK activity is modulated by upstream signals such as insulin, glucocorticoids, AMPK, and the circadian clock (CLOCK/BMAL1). BCKDK interacts with BCKDHA and DBT (dihydrolipoamide branched chain transacylase E2) within the BCKD complex. By controlling BCAA levels, especially leucine, BCKDK indirectly regulates mTORC1 signaling, since leucine is a key allosteric activator of mTORC1. Thus, BCKDK integrates nutritional and hormonal cues with cellular growth pathways.
In SK-HEP-1 liver cancer cells, BCKDK knockout relieves inhibition of BCKDC, enhancing BCAA oxidation and reducing intracellular BCAA pools. This metabolic shift attenuates mTORC1 activity, reflected by decreased phosphorylation of downstream effectors such as S6K (p-S6K) and 4E-BP1 (p-4EBP1). The polyclonal knockout model therefore enables dissection of how BCKDK-dependent BCAA metabolism influences liver cancer cell proliferation, nutrient sensing, and metabolic flux. Given the prominent role of mTORC1 in hepatocellular carcinoma progression, these cells are a valuable tool for probing links between BCAA catabolism and hepatic tumor biology.
These cells are suitable for a range of assays: western blotting and RT-qPCR for confirming BCKDK disruption and assessing pathway components, LC-MS-based BCAA quantification, phospho-signaling analysis (p-S6K, p-4EBP1), cell proliferation assays, and metabolic flux analysis using stable isotope tracers. Applications include mechanistic studies of BCAA metabolism in liver cancer, investigation of mTORC1-mediated growth signaling, validation of BCKDK as a therapeutic target in metabolic disorders and cancer, and screening of pharmacological modulators. For further information, please contact Ascent Research.
